Abstract
Background: Inflammatory demyelinating diseases of the central nervous system (CNS) are autoimmune conditions leading to significant neurological disability in adults. Recent classifications include myelin oligodendrocyte glycoprotein antibody associated disease (MOGAD) and neuromyelitis optica spectrum disorder (NMOSD) which pose diagnostic challenges due to overlapping clinical and radiological features. This study aimed to assess the clinical spectrum among adults and children diagnosed with CNS demyelinating diseases and to find the proportion of MOG and/or aquaporin-4 (AQP4) autoantibodies amongst them.
Methods: This single-center, retrospective study examined 20 patients diagnosed with CNS demyelinating disorders between March, 2023 and February, 2024. Data pertaining to demographics, disease types, CSF analysis, MRI findings, treatment modalities, and serological profiles for anti-AQP4 and anti-MOG antibodies were collected from hospital records and evaluated.
Results: Among 20 patients [median age, 34 years (IQR, 18.75); males (n=10) and females (n=10)], acute transverse myelitis (TM) was the most common demyelinating disorder at onset (60%) followed by optic neuritis (ON) (20%). CSF analysis found elevated protein levels in 53% and pleocytosis in 33% of patients. MRI findings revealed longitudinal extensive involvement in 52% of patients, predominantly affecting the cervical and dorsal spine. Serological testing identified 15% positive for anti-AQP4 and 10% for anti-MOG antibodies. MOG+ patients were significantly younger than AQP4+ patients (mean age 16.5 vs. 36.66 years, p=0.016). Both MOG+ patients were male, with 50% presenting with acute TM and 50% with acute disseminated encephalomyelitis. Among AQP4+ patients, the male-to-female ratio was 1:2, with 66.66% presenting with acute TM and 33.33% with ON.
Conclusion: CNS demyelinating disorders primarily affect younger individuals, with TM as the most common initial disorder and extensive spinal involvement in cervical and dorsal regions. Serological testing identified three patients with anti-AQP4 and two with anti-MOG antibodies, providing valuable insights into the clinical spectrum of these disorders through cell-based assays.
Downloads
References
- Boey K, Shiokawa K, Rajeev S. Leptospira infection in rats: a literature review of global prevalence and distribution. PLoS Negl Trop Dis. 2019;13(8). doi: 10.1371/journal.pntd.0007499.
- Kim SM, Woodhall MR, Kim JS, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm 2015;2(6):e163. DOI: 10.1212/NXI.0000000000000163.
- T. Murali Venkateswara Rao, U. Ganga Prasad. Clinical profile of 50 adults with demyelinating diseases of central nervous system-a prospective observational study. International Archives of Integrated Medicine 2016; 3(11): 143-50.
- Yılmaz Ü. The diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in children. Explor Neuroprot Ther 2024;4:38–54. DOI: 10.37349/ent.2024.00069
- Jain RS, Jain D, Murarka S, et al. Comparison of clinical and radiological features of aquaporin4 (AQP-4) antibody positive neuromyelitis optica spectrum disorder (NMOSD) and anti myelin oligodendrocyte glycoprotein (Anti-MOG) syndrome-our experience from Northwest India. Ann Indian Acad Neurol 2022;25(2):246-55. DOI: 10.4103/aian.aian_860_21.
- Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012;69(2):239-45. DOI: 10.1001/archneurol.2011.216.
- Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014;261(1):1-16. DOI: 10.1007/s00415-013-7169-7.
- Misu T, Höftberger R, Fujihara K, et al. Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol 2013;125(6):815-27. DOI: 10.1007/s00401-013-1116-7.
- Reindl M, Rostasy K. MOG antibody-associated diseases. Neurol Neuroimmunol Neuroinflamm 2015;2(1):e60. DOI: 10.1212/NXI.0000000000000060.
- Di Pauli F, Höftberger R, Reindl M, et al. Fulminant demyelinating encephalomyelitis: Insights from antibody studies and neuropathology. Neurol Neuroimmunol Neuroinflamm 2015;2(6):e175. DOI: 10.1212/NXI.0000000000000175.
- Dhar N, Kumar M, Tiwari A, et al. Comparison of clinico-radiological profile, optical coherence tomography parameters, and outcome in MOGAD and Neuromyelitis optica spectrum disorder subtypes: A prospective observational study. J Neurosci Rural Pract 2023;14(2):239-51. DOI: 10.25259/JNRP_8_2022.
- Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85(2):177-89. doi: 10.1212/WNL.0000000000001729.
- Zhou Z, Qian D, Liu L, et al. Central nervous system inflammatory demyelinating diseases with stroke-like onset and their responses to thrombolysis. Neurol Sci 2015;36(10):1943-7. DOI: 10.1007/s10072-015-2293-z.
- Koudriavtseva T, Renna R, Plantone D, et al. Demyelinating and thrombotic diseases of the central nervous system: common pathogenic and triggering factors. Front Neurol 2015;6:63. DOI: 10.3389/fneur.2015.00063.
- Haines JD, Vidaurre OG, Zhang F, et al. Multiple sclerosis patient-derived CSF induces transcriptional changes in proliferating oligodendrocyte progenitors. Mult Scler 2015;21(13):1655-69. DOI: 10.1177/1352458515573094.
- Pandit L, Sato DK, Mustafa S, et al. Serological markers associated with neuromyelitis optica spectrum disorders in South India. Ann Indian Acad Neurol 2016;19(4):505-9. DOI: 10.4103/0972-2327.192389.
- Nagireddy RBR, Kumar A, Singh VK, et al. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature. J Neuroimmunol 2021;361:577742. DOI: 10.1016/j.jneuroim.2021.577742.
- Gasperi C, Salmen A, Antony G, et al. Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis. JAMA Neurol 2019;76(7):841-9. DOI: 10.1001/jamaneurol.2019.0905.
- Shi Q, Tian C, Huang X, et al. Analysis of cerebrospinal fluid carbohydrate antigen series biomarkers in non-neoplastic diseases. Ann Clin Lab Sci 2015;45(6):623-6. PMID: 26663790.
- Stilund M, Gjelstrup MC, Petersen T, et al. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel. PLoS One 2015;10(4):e0119681. DOI: 10.1371/journal.pone.0119681.
- Burman J, Svenningsson A. Cerebrospinal fluid concentration of Galectin-9 is increased in secondary progressive multiple sclerosis. J Neuroimmunol 2016;292:40-4. DOI: 10.1016/j.jneuroim.2016.01.008.
- Fadda G, Flanagan EP, Cacciaguerra L, et al. Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD. Front Neurol 2022;13:1011579. DOI: 10.3389/fneur.2022.1011579.
- Gass A, Rocca MA, Agosta F, et al. MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis. Lancet Neurol 2015;14(4):443-54. DOI: 10.1016/S1474-4422(14)70294-7.
- Pohl D. Epidemiology, immunopathogenesis and management of pediatric central nervous system inflammatory demyelinating conditions. Curr Opin Neurol 2008;21(3):366-72. doi: 10.1097/WCO.0b013e3282fd172b.
- Pandit L, Kundapur R. Prevalence and patterns of demyelinating central nervous system disorders in urban Mangalore, South India. Mult Scler 2014;20(12):1651-3. DOI: 10.1177/1352458514521503.
- Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014;71(3):276-83. DOI: 10.1001/jamaneurol.2013.5857.
- Dauby S, Dive D, Lutteri L, et al. Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort. Acta Neurol Belg 2022;122(1):135-44. DOI: 10.1007/s13760-021-01712-3.
